AVIR

Atea Pharmaceuticals, Inc.

• TipRanks·20h ago

  Atea Pharmaceuticals Eyes 2028 Launch After Strong Phase 3

• Dow Jones·08/13 14:25

  Atea Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley

• Dow Jones·08/13 14:25

  Atea Pharmaceuticals Price Target Raised to $7.00/Share From $6.00 by Morgan Stanley

• Benzinga·08/13 14:15

  Morgan Stanley Maintains Equal-Weight on Atea Pharmaceuticals, Raises Price Target to $7

• TipRanks·08/13 11:56

  Atea Pharmaceuticals (AVIR) Receives a Hold from Morgan Stanley

• TipRanks·08/12 23:30

  Analysts’ Top Healthcare Picks: Cardinal Health (CAH), Atea Pharmaceuticals (AVIR)

• Seeking Alpha·08/12 20:15

  Atea Pharmaceuticals GAAP EPS of -$0.41 beats by $0.15

• Dow Jones·08/12 20:05

  Press Release: Atea Pharmaceuticals Reports -2-

• Seeking Alpha·08/12 14:00

  Here are the major earnings after the close Wednesday

• TipRanks·07/31 16:30

  Atea’s Renal and Hepatic Impairment Study Marks a Key De-Risking Step for AVIR Investors

• Seeking Alpha·07/28 15:50

  Atea drops despite late-stage trial win for hepatitis C therapy

• TipRanks·07/28 15:10

  Analysts Are Bullish on These Healthcare Stocks: Opko Health (OPK), Atea Pharmaceuticals (AVIR)

• Benzinga·07/28 14:13

  Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial

• Dow Jones·07/28 11:41

  Atea Pharmaceuticals Shares Positive Results from Hepatitis C Trial

• TipRanks·07/28 11:21

  Atea Pharmaceuticals reports C-BEYOND trial meets primary, secondary endpoints